FRANKLIN LAKES, N.J., May 24, 2011 /PRNewswire/ — Medco
Chairman and CEO David B. Snow Jr. today recapped a string of
accomplishments in 2010 for attendees at the company’s annual
shareholders’ meeting and offered a vision for a future in which
Medco plays a pivotal role in the success of healthcare reform.
“There are moments in history when multiple factors align to fuel
positive change,” he said. “We’re living in one of those moments;
Medco is seizing this opportunity for its clients and patients as
we advance high-quality healthcare through innovation.”
(Logo: http://photos.prnewswire.com/prnh/20100609/MEDCOLOGO)
Snow brought shareholders a vivid sense of the abundant
opportunities that lie ahead for Medco and its clients in all areas
of its business, leading with the potential to reap unprecedented
savings from a historical wave of first-time generic drugs
beginning late this year. Snow highlighted Medco’s ability to
leverage its wired pharmacy to drive even greater client savings
and clinical benefits and utilize its vast prescription drug and
medical databases to help patients and physicians close 2.3 million
gaps in care in 2010 through its robust set of sophisticated
clinical tools designed to reduce overall healthcare costs.
The Medco Medicare Prescription Drug Plan (PDP)® is the
first and only national plan to earn a 5-Star overall rating from
the Center for Medicare and Medicaid Services – a designation
for providing members with the highest overall service quality and
performance. The company also expanded its comparative
effectiveness and outcomes research capabilities with the
acquisition of United BioSource Corporation, and its expanded
genomic research and health management capabilities through the
Medco Research Institute and its acquisition of DNA Direct,
initiatives designed to drive further value to clients and the
healthcare system.
“By
‘/>”/>
SOURCE
